Marksans Pharma Limited

Informe acción NSEI:MARKSANS

Capitalización de mercado: ₹73.6b

Marksans Pharma Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Marksans Pharma de 18.6% y 12% por año respectivamente. Se prevé que el BPA crezca en un 18.5% al año. Se espera que la rentabilidad financiera sea de 15.6% en 3 años.

Información clave

18.6%

Tasa de crecimiento de los beneficios

18.45%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals15.6%
Tasa de crecimiento de los ingresos12.0%
Rentabilidad financiera futura15.57%
Cobertura de analistas

Low

Última actualización20 Jan 2026

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Recent updates

Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon

Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today

Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today

Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year

Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares

Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)

We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings

₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results

Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?

May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?

Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly

Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark

Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark

Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
User avatar

Teva Pharma Facility And US Expansion To Strengthen Future Outlook

Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Previsiones de crecimiento de beneficios e ingresos

NSEI:MARKSANS - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
3/31/202836,3755,5554,2145,0293
3/31/202732,0464,6893,3254,3683
3/31/202628,1123,8763,4864,2843
9/30/202527,3073,5173462,047N/A
6/30/202526,5223,501N/AN/AN/A
3/31/202526,2283,8063372,067N/A
12/31/202424,7443,683N/AN/AN/A
9/30/202423,7873,4705202,169N/A
6/30/202422,6803,338N/AN/AN/A
3/31/202421,7743,1372162,304N/A
12/31/202321,0343,164N/AN/AN/A
9/30/202319,9712,9658942,528N/A
6/30/202319,1842,743N/AN/AN/A
3/31/202318,5212,6631,8382,374N/A
12/31/202217,8422,123N/AN/AN/A
9/30/202216,6702,0049721,286N/A
6/30/202215,7561,847N/AN/AN/A
3/31/202214,9081,868529993N/A
12/31/202114,0692,367N/AN/AN/A
9/30/202114,0262,4738831,336N/A
6/30/202114,0642,518N/AN/AN/A
3/31/202113,7622,3851,3221,786N/A
12/31/202013,8172,018N/AN/AN/A
9/30/202013,1421,7241,8392,478N/A
6/30/202012,2031,476N/AN/AN/A
3/31/202011,3441,2081,7342,333N/A
12/31/201910,463879N/AN/AN/A
9/30/20199,97283466416N/A
6/30/201910,099780N/AN/AN/A
3/31/201910,001804N/A274N/A
12/31/20189,523666N/AN/AN/A
9/30/20189,223582N/AN/AN/A
6/30/20189,272463N/AN/AN/A
3/31/20189,127358N/A501N/A
12/31/20178,918343N/AN/AN/A
9/30/20178,949275N/AN/AN/A
6/30/20178,015187N/AN/AN/A
3/31/20177,672113N/A141N/A
12/31/20167,92670N/AN/AN/A
9/30/20167,948136N/AN/AN/A
6/30/20168,699481N/AN/AN/A
3/31/20168,933785N/A308N/A
12/31/20158,5361,093N/AN/AN/A
9/30/20158,4951,191N/AN/AN/A
6/30/20158,0451,154N/AN/AN/A
3/31/20157,9671,094N/A1,545N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.6% al año) de MARKSANS es superior a la tasa de ahorro (6.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (18.6% al año) de MARKSANS crezcan más rápidamente que el mercado Indian (16.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de MARKSANS crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (12% al año) de MARKSANS crezcan más rápidamente que los del mercado Indian (10.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12% al año) de MARKSANS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MARKSANS sea baja dentro de 3 años (15.6%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/01/28 05:51
Precio de las acciones al final del día2026/01/28 00:00
Beneficios2025/09/30
Ingresos anuales2025/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Marksans Pharma Limited está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Ranjit KapadiaCentrum Broking Limited
Deepika MurarkaChoice Equity Broking Private Limited
Maitri ShethChoice Equity Broking Private Limited